Shire Human Genetic Therapies Inc.; est. no. 1593

Shire Human Genetic Therapies Inc. - 205 Alewife Brook Parkway, Cambridge, MA 02138; formerly Transkaryotic Therapies, Inc. (TKT), which was acquired in April 2005 by Shire Pharmaceuticals Group plc for ~$1.6 billion

Related product monographs:

1. EPO, rDNA/TKT -- R&D ; Tech.
2. Galactosidase, alfa, rDNA -- Manuf. ; R&D
3. Glucocerebrosidase, rDNA/Shire -- Manuf. ; R&D ; Tech. ; USA mark.
4. Iduronate-2-sulfatase, rDNA -- Manuf. ; R&D ; Tech.

Location - Cambridge MA 02138 USA

Further information:
Description, ordering information, etc.
Order/Inquiry
Products Database

Copyright ©2020. Biotechnology Information Institute